AVITA Medical’s Investigational Device Exemption (IDE) Application Approved by US FDA for Clinical Feasibility Study Evaluating RECELL System for Vitiligo.





  • Regenerative medicine company, AVITA Medical Limited (ASX: AVH) received US FDA Investigational Device Exemption (IDE) Application approval for conducting a feasibility study evaluating the safety and effectiveness of its RECELL® Autologous Cell Harvesting Device (RECELL® System) used for repigmentation of depigmented lesions associated with stable vitiligo.
  • The company is expecting to initiate the study in first half of financial year 2020.
  • Avita Medical would conduct a pilot study with ten patients with vitiligo lesions that have been stable for minimum one year by collaborating with leading medical centres.
  • This study is based on previous peer-reviewed, published efficacy results confirming the possibility of RECELL as a cure for repigmentation with stable vitiligo.


All pictures are copyright to their respective owner(s).Kalkinemedia.com does not claim ownership of any of the pictures displayed on this website unless stated otherwise. Some of the images used on this website are taken from the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image.


There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.

Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.

As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK